Eikon Therapeutics, Inc. Common Stock (EIKN) vs NeuroPace, Inc. (NPCE)
A side-by-side comparison of Eikon Therapeutics, Inc. Common Stock and NeuroPace, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EIKN
Eikon Therapeutics, Inc. Common Stock
$7.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
NPCE
NeuroPace, Inc.
$12.67HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EIKN vs NPCE
growth of $100 · dividends reinvested · last 1yEIKN -49.7% (-49.7%/yr)NPCE -17.8% (-17.8%/yr)NPCE compounded faster over this window
EIKN NPCE
EIKN vs NPCE: by the numbers
- •NPCE is the larger company ($432M vs $407M market cap).
- •Both run net losses; EIKN's is the smaller (0.00% vs -19.34% net margin).
Metrics side by side
Valuation
| Metric | EIKN | NPCE |
|---|---|---|
| P/S ratio | N/A | 4.37 |
| P/B ratio | 0.87 | 36.35 |
Profitability
| Metric | EIKN | NPCE |
|---|---|---|
| Gross margin | 0.00% | 79.63% |
| Operating margin | 0.00% | -15.26% |
| Net margin | 0.00% | -19.34% |
| ROE | -69.06% | -160.85% |
| ROIC | -46.16% | -18.95% |
Growth (annualized)
| Metric | EIKN | NPCE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 15.85% |
| Total return CAGR (5Y) | N/A | -4.94% |
Go deeper
Dig into the metrics
Eikon Therapeutics, Inc. Common Stock ROENeuroPace ROEEikon Therapeutics, Inc. Common Stock operating marginNeuroPace operating marginEikon Therapeutics, Inc. Common Stock revenue growthNeuroPace revenue growthEikon Therapeutics, Inc. Common Stock free cash flowNeuroPace free cash flow
Eikon Therapeutics, Inc. Common Stock & NeuroPace appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.